Suppr超能文献

白细胞介素-36在慢性炎症和纤维化中的作用——填补差距?

IL-36 in chronic inflammation and fibrosis - bridging the gap?

作者信息

Elias Michael, Zhao Shuai, Le Hongnga T, Wang Jie, Neurath Markus F, Neufert Clemens, Fiocchi Claudio, Rieder Florian

机构信息

Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA.

出版信息

J Clin Invest. 2021 Jan 19;131(2). doi: 10.1172/JCI144336.

Abstract

IL-36 is a member of the IL-1 superfamily and consists of three agonists and one receptor antagonist (IL-36Ra). The three endogenous agonists, IL-36α, -β, and -γ, act primarily as proinflammatory cytokines, and their signaling through the IL-36 receptor (IL-36R) promotes immune cell infiltration and secretion of inflammatory and chemotactic molecules. However, IL-36 signaling also fosters secretion of profibrotic soluble mediators, suggesting a role in fibrotic disorders. IL-36 isoforms and IL-36 have been implicated in inflammatory diseases including psoriasis, arthritis, inflammatory bowel diseases, and allergic rhinitis. Moreover, IL-36 has been connected to fibrotic disorders affecting the kidney, lung, and intestines. This review summarizes the expression, cellular source, and function of IL-36 in inflammation and fibrosis in various organs, and proposes that IL-36 modulation may prove valuable in preventing or treating inflammatory and fibrotic diseases and may reveal a mechanistic link between inflammation and fibrosis.

摘要

白细胞介素-36(IL-36)是白细胞介素-1超家族的成员,由三种激动剂和一种受体拮抗剂(IL-36Ra)组成。三种内源性激动剂,即IL-36α、-β和-γ,主要作为促炎细胞因子发挥作用,它们通过IL-36受体(IL-36R)发出的信号促进免疫细胞浸润以及炎症和趋化分子的分泌。然而,IL-36信号传导也促进促纤维化可溶性介质的分泌,提示其在纤维化疾病中发挥作用。IL-36同工型和IL-36已被证实与包括银屑病、关节炎、炎症性肠病和变应性鼻炎在内的炎症性疾病有关。此外,IL-36还与影响肾脏、肺和肠道的纤维化疾病相关。本综述总结了IL-36在各种器官的炎症和纤维化中的表达、细胞来源及功能,并提出调节IL-36可能对预防或治疗炎症性和纤维化疾病具有重要价值,且可能揭示炎症与纤维化之间的机制联系。

相似文献

1
IL-36 in chronic inflammation and fibrosis - bridging the gap?
J Clin Invest. 2021 Jan 19;131(2). doi: 10.1172/JCI144336.
3
The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases.
Ann N Y Acad Sci. 2018 Apr;1417(1):23-34. doi: 10.1111/nyas.13280. Epub 2016 Oct 26.
4
Emerging Role of the IL-36/IL-36R Axis in Multiple Inflammatory Skin Diseases.
J Invest Dermatol. 2024 Feb;144(2):206-224. doi: 10.1016/j.jid.2023.11.004. Epub 2024 Jan 7.
5
The role of interleukin-36 in health and disease states.
J Eur Acad Dermatol Venereol. 2024 Oct;38(10):1910-1925. doi: 10.1111/jdv.19935. Epub 2024 May 23.
6
The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium.
Ann Rheum Dis. 2013 Sep 1;72(9):1569-74. doi: 10.1136/annrheumdis-2012-202264. Epub 2012 Dec 25.
7
Regulation and function of interleukin-36 cytokines.
Immunol Rev. 2018 Jan;281(1):169-178. doi: 10.1111/imr.12610.
8
Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis.
PLoS One. 2014 Aug 11;9(8):e101954. doi: 10.1371/journal.pone.0101954. eCollection 2014.
9
Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions.
Cytokine. 2022 Aug;156:155897. doi: 10.1016/j.cyto.2022.155897. Epub 2022 Jun 6.
10
Interleukin-36: Structure, Signaling and Function.
Adv Exp Med Biol. 2021;21:191-210. doi: 10.1007/5584_2020_488.

引用本文的文献

1
IL-36/IL-36R signaling promotes CD4 T cell-dependent colitis via pro-inflammatory cytokine production.
Front Immunol. 2025 Jun 26;16:1604332. doi: 10.3389/fimmu.2025.1604332. eCollection 2025.
3
The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis.
Adv Sci (Weinh). 2025 Aug;12(30):e05067. doi: 10.1002/advs.202505067. Epub 2025 May 20.
6
Inflammation-fibrosis interplay in inflammatory bowel disease: mechanisms, progression, and therapeutic strategies.
Front Pharmacol. 2025 Feb 28;16:1530797. doi: 10.3389/fphar.2025.1530797. eCollection 2025.
9
Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions.
Dermatol Ther (Heidelb). 2025 Feb;15(2):395-411. doi: 10.1007/s13555-024-01325-7. Epub 2025 Feb 10.
10
Advances in understanding the role of interleukins in pulmonary fibrosis (Review).
Exp Ther Med. 2024 Nov 28;29(2):25. doi: 10.3892/etm.2024.12775. eCollection 2025 Feb.

本文引用的文献

1
Interleukin-38 inhibits adipogenesis and inflammatory cytokine production in 3T3-L1 preadipocytes.
Cell Biol Int. 2020 Nov;44(11):2357-2362. doi: 10.1002/cbin.11428. Epub 2020 Jul 31.
2
The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis.
J Clin Invest. 2020 Nov 2;130(11):5765-5781. doi: 10.1172/JCI134217.
4
Keratinocyte interleukin-36 receptor expression orchestrates psoriasiform inflammation in mice.
Life Sci Alliance. 2020 Feb 21;3(4). doi: 10.26508/lsa.201900586. Print 2020 Apr.
5
Interleukin-36 receptor antagonist alleviates airway inflammation in asthma via inhibiting the activation of Interleukin-36 pathway.
Int Immunopharmacol. 2020 Apr;81:106200. doi: 10.1016/j.intimp.2020.106200. Epub 2020 Feb 7.
6
Interleukin-36: Structure, Signaling and Function.
Adv Exp Med Biol. 2021;21:191-210. doi: 10.1007/5584_2020_488.
8
IL-36α contributes to enhanced T helper 17 type responses in allergic rhinitis.
Cytokine. 2020 Apr;128:154992. doi: 10.1016/j.cyto.2020.154992. Epub 2020 Jan 23.
9
Interleukin-38 is elevated in inflammatory bowel diseases and suppresses intestinal inflammation.
Cytokine. 2020 Mar;127:154963. doi: 10.1016/j.cyto.2019.154963. Epub 2020 Jan 9.
10
Function and Regulation of IL-36 Signaling in Inflammatory Diseases and Cancer Development.
Front Cell Dev Biol. 2019 Dec 4;7:317. doi: 10.3389/fcell.2019.00317. eCollection 2019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验